中国艾滋病诊疗指南（2024版）

doi:10.19871/j.cnki.xfcrbzz.2024.04.014

摘要/Abstract

摘要： 中华医学会感染病学分会艾滋病学组于2005年制订了我国《艾滋病诊疗指南》（简称《指南》）,2024版《指南》是在2021年第5版《指南》的基础上参照国内外最新研究进展修订而成。新版《指南》重点对抗病毒治疗、全程管理、机会性感染、HIV感染合并肿瘤、HIV感染的预防与干预等内容进行了更新,并新增“艾滋病免疫重建不全（immunological non-responder,INR）”等内容,首次提出了“艾滋病脆弱人群”的概念,增加了诊治推荐意见及其推荐证据和推荐强度。《指南》包括流行病学、病原学特征、实验室检测、发病机制、临床表现与分期、诊断标准、常见机会性感染、抗病毒治疗、免疫重建炎性综合征、INR、艾滋病相关肿瘤、HIV母婴垂直传播阻断及单阳家庭生育、HIV暴露前后预防与阻断、HIV感染的全程管理等14个方面的内容。本《指南》旨在帮助临床医师在艾滋病诊治和管理中合理决策,《指南》也将根据国内外的研究进展定期进行修订与更新。

关键词: 获得性免疫缺陷综合征, 人类免疫缺陷病毒, 诊断, 治疗, 指南

Abstract: Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association, formulated the "Chinese guidelines for the diagnosis and treatment of AIDS" (here in after referred to as the "Guidelines") in 2005. The 2024 edition of the Guidelines was revised based on the 5th edition published in 2021, taking into account the latest research progress both domestically and internationally. The new edition of the Guidelines focuses on updating aspects such as antiviral therapy, comprehensive management, opportunistic infections, AIDS-related tumors, prevention and intervention of HIV infection, and introduces new content on "immunological non-responder (INR)". It also introduces the concept of "vulnerable populations with AIDS" for the first time, and adds recommendations for diagnosis and treatment along with the supporting evidence and strength of recommendation.The Guidelines encompass 14 aspects including epidemiology, characteristics of the pathogen, laboratory testing, disease mechanism, clinical manifestations and staging, diagnostic criteria, common opportunistic infections, antiviral therapy, immune reconstitution inflammatory syndrome, INR, AIDS-related tumors, prevention of mother-to-child transmission of HIV and reproductive planning for serodiscordant couples, pre- and post-exposure prophylaxis and prevention of HIV, and comprehensive management of HIV infection. These Guidelines aim to assist clinicians in making reasonable decisions regarding the diagnosis and management of AIDS, and will be regularly updated and revised according to research advancements at home and abroad.

Key words: Acquired immunodeficiency syndrome, Human immunodeficiency virus, Diagnosis, Treatment, Guidelines

中图分类号:

R512.91

中华医学会感染病学分会艾滋病学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南（2024版）[J]. 新发传染病电子杂志, 2024, 9(4): 68-94.

Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control, Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2024 edition)[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(4): 68-94.

参考文献

[1] 沈银忠，李太生.从我国艾滋病诊疗指南的变迁看艾滋病防治工作的进展与成效[J/CD].新发传染病电子杂志，2022, 7（3）:1-5.
[2] UNAIDS. Global HIV & AIDS statistics: Fact sheet[EB/OL]. [2024-02-16]. https://www.unaids.org/en/resources/fact-sheet.
[3] POLITICAL DECLARATION ON HIV AND AIDS: ending inequalities and getting on track to end AIDS by 2030[EB/OL]. (2021-07-08)[2024-02-16].https://undocs.org/A/RES/75/284.
[4] 梁焱铃, 冯毅, 邵一鸣. HIV-1 C亚型、CRF07_BC和CRF08_BC重组毒株的起源和分子流行病学研究进展[J].中国艾滋病性病,2021,27(5):549-552.
[5] 钟平. HIV分子流行病学研究和实践进展[J/CD].新发传染病电子杂志, 2019, 4(3):137-144.
[6] VRANCKEN B, ZHAO B, LI X, et al. Comparative circulation dynamics of the five main HIV types in China[J]. J Virol, 2020, 94(23) :e00683-20.
[7] 梁淑家,辛若雷. HIV-1 CRF55_01B毒株流行特征的研究进展[J].实用预防医学，2022，29(6)：766-769.
[8] 粟斌, 吴昊, 张彤. HIV-2型感染流行病学诊疗方案及防控策略[J]. 中国艾滋病性病, 2019，25（7）：756-759.
[9] 中国疾病预防控制中心．全国艾滋病检测技术规范(2020年修订版)[EB/OL]. (2020-05-18)[2024-03-09]．http://ncaids.chinacdc.cn/zxzx/zxdteff/202005/W020200522484711502629.pdf.
[10] 荆凡辉，吕玮，李太生. HIV感染者免疫功能重建新视角：CD4/CD8比值[J]．中国艾滋病性病， 2018,24(6):643-646.
[11] PANEL ON ANTIRETROVIRAL GUIDELINES FOR ADULTS AND ADOLESCENTS. GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN ADULTS AND ADOLESCENTS LIVING WITH HIV. Department of Health and Human Services[EB/OL].[2024-02-18].https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new.
[12] GANDHI RT, BEDIMO R, HOY JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 Recommendations of the International Antiviral Society-USA Panel[J]. JAMA, 2023,329(1):63-84.
[13] LI Y, HAN Y, XIE J, et al. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission[J]. AIDS, 2014, 28(4):521-530.
[14] SU B, DISPINSERI S, IANNONE V, et al. Update on Fc-mediated antibody functions against HIV-1 beyond neutralization[J]. Front Immunol, 2019, 10:2968.
[15] YANG X, SU B, ZHANG X, et al. Incomplete immune reconstitution in HIV感染/AIDS patients on antiretroviral therapy: challenges of immunological non-responders[J]. J Leukoc Biol, 2020, 107(4):597-612.
[16] 国家卫生健康委员会. 艾滋病和艾滋病病毒感染诊断WS 293—2019[S/OL]．(2019-01-02) [2024-03-28]. http://www.nhc.gov.cn/wjw/s9491/201905/6430aa653728439c901a7340796e4723/files/84dffca4fb2c4293abb6be4d5353f924.pdf.
[17] PANEL ON OPPORTUNISTIC INFECTIONS IN ADULTS AND ADOLESCENTS WITH HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[EB/OL]. [2024-02-18].https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new.
[18] DATTA D, ALI SA, HENKEN EM, et al. Pneumocystis carinii pneumonia: the time course of clinical and radiographic improvement[J]. Chest, 2003, 124(5):1820-1823.
[19] 逄晓莉, 张哲, 肖江, 等. 获得性免疫缺陷综合征合并肺孢子菌性肺炎患者病情影响因素[J/OL]中华实验和临床感染病杂志（电子版）, 2019, 13(5)：396-401.
[20] ESTEVES F, LEE CH, DE SOUSA B, et al. (1-3)-beta-D-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia (PcP) in HIV-infected patients[J]. Eur J Clin Microbiol Infect Dis, 2014, 33(7):1173-1180.
[21] JUNIPER T, EADES CP, GIL E, et al. Use of β-D-glucan in diagnosis of suspected Pneumocystis jirovecii pneumonia in adults with HIV infection[J]. Int J STD AIDS, 2021, 32(11):1074-1077.
[22] YANG DH, XU Y, HONG L, et al. Efficacy of caspofungin combined with clindamycin for Pneumocystis jirovecii pneumonia in a systemic lupus erythematosus patient: a case report and literature review[J]. Respir Med Case Rep, 2019, 26:108-111.
[23] MCTAGGART LR, WENGENACK NL, RICHARDSON SE. Validation of the MycAssay Pneumocystis kit for detection of Pneumocystis jirovecii in bronchoalveolar lavage specimens by comparison to a laboratory standard of direct immunofluorescence microscopy, real-time PCR, or conventional PCR[J]. J Clin Microbiol, 2012, 50(6):1856-1859.
[24] 何礼贤. 肺孢子菌肺炎的诊断与治疗[J] . 中华结核和呼吸杂志, 2007, 30(11) : 802-805.
[25] 中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J]. 中华传染病杂志, 2022, 40(1)：6-19.
[26] WORLD HEALTH ORGANIZATION. WHO operational handbook on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detention, 2021 update[M/OL]. [2024-02-18]. https://www.who.int/publications/i/item/9789240030589.
[27] DORMAN SE, NAHID P, KURBATOVA EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis[J]. N Engl J Med, 2021,384(18):1705-1718.
[28] PETTIT AC, PHILLIPS P, KURBATOVA E, et al. Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with human immunodeficiency virus (S31/A5349)[J]. Clin Infect Dis, 2023,76(3):e580-e589.
[29] WORLD HEALTH ORGANIZATION. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach [M/OL]. [2024-02-18]. https://www.who.int/publications/i/item/9789240031593.
[30] WORLD HEALTH ORGANIZATION.WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-susceptible tuberculosis treatment[M/OL]. [2024-02-18]. https://www.who.int/publications/i/item/9789240048126.
[31] EUROPEAN AIDS CLINICAL SOCIETY. EACS Guidelines(Version 12.0) [EB/OL]. [2024-02-18]. https://www.eacsociety.org/media/guidelines-12.0.pdf.
[32] 中华医学会热带病与寄生虫学分会艾滋病学组. 人类免疫缺陷病毒/艾滋病患者合并非结核分枝杆菌感染诊治专家共识[J]. 中华传染病杂志，2019，37(3):129-138.
[33] 中国医师协会皮肤科医师分会带状疱疹专家共识工作组. 带状疱疹中国专家共识[J]. 中华皮肤科杂志,2018,51(6)：403-408.
[34] WANG YF, CAI JP, WANG YD, et al. Immunoassays based on Penicillium marneffei Mp1p derived from Pichia pastoris expression system for diagnosis of penicilliosis[J]. PLoS One, 2011,6(12):e28796.
[35] PAPPAS PG, KAUFFMAN CA, ANDES DR, et al. Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016,62(4):e1-50.
[36] 中华医学会感染病学分会. 隐球菌性脑膜炎诊治专家共识[J]. 中华传染病杂志,2018,36(4)：193-199.
[37] CHANG CC, HARRISON TS, BICANIC TA, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM[J/OL]. Lancet Infect Dis, 2024(2024-02-09)[2024-03-28]. https://doi.org/10.1016/S1473-3099(23)00731-4. [published online ahead of print].
[38] JARVIS JN, LAWRENCE DS, MEYA DB, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis[J]. N Engl J Med, 2022,386(12):1109-1120.
[39] WORLD HEALTH ORGANIZATION. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV[EB/OL].[2024-02-22]. https://www.who.int/publications/i/item/9789240052178.
[40] BEARDSLEY J, WOLBERS M, KIBENGO FM, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis[J]. N Engl J Med, 2016,374(6):542-554.
[41] BOULWARE DR, MEYA DB, MUZOORA C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis[J]. N Engl J Med, 2014, 370(26):2487-2498.
[42] CHANG CC, DORASAMY AA, GOSNELL BI, et al. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome[J]. AIDS, 2013, 27(13):2089-2099.
[43] OUYANG Y, CAI S, LIANG H, et al. Administration of voriconazole in disseminated Talaromyces (Penicillium) marneffei infection: a retrospective study[J]. Mycopathologia, 2017,182(5/6):569-575.
[44] KLUS J, LY VT, CHAN C, et al. Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort[J]. Med Mycol, 2021,59(4):392-399.
[45] LE T, KINH NV, CUC N, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis[J]. N Engl J Med, 2017,376(24):2329-2340.
[46] TUN N, MCLEAN A, DEED X, et al. Is stopping secondary prophylaxis safe in HIV-positive talaromycosis patients? Experience from Myanmar[J]. HIV Med, 2020,21(10):671-673.
[47] 中国疾病预防控制中心性病艾滋病预防控制中心. 国家免费艾滋病抗病毒药物治疗手册[M]. 5版. 北京：人民卫生出版社，2023.
[48] PANEL ON ANTIRETROVIRAL THERAPY AND MEDICAL MANAGEMENT OF CHILDREN LIVING WITH HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection[EB/OL].[2024-02-18] https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new.
[49] DOOLEY KE, KAPLAN R, MWELASE N, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial[J]. Clin Infect Dis, 2020,70(4):549-556.
[50] DE CASTRO N, MARCY O, CHAZALLON C, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial[J]. Lancet Infect Dis, 2021,21(6):813-822.
[51] POZNIAK A, MEINTJES G. Raltegravir in patients with tuberculosis[J]. Lancet Infect Dis, 2021,21(6):748-749.
[52] SURIAL B, BéGUELIN C, CHAVE JP, et al. Brief report: switching from TDF to TAF in HIV/HBV-coinfected individuals with renal dysfunction-a prospective cohort study[J]. J Acquir Immune Defic Syndr, 2020,85(2):227-232.
[53] AVIHINGSANON A, LU H, LEONG CL, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial[J]. Lancet HIV, 2023, 10(10):e640-e652.
[54] 李航, 张福杰, 卢洪洲, 等. HIV感染合并慢性肾脏病患者管理专家共识[J].中国艾滋病性病, 2017, 23(6):578-581.
[55] AMELE S, PETERS L, RODGER A, et al. Effectiveness and safety of interferon-free direct-acting antiviral hepatitis C virus therapy in HIV/hepatitis C virus coinfected individuals: results from a pan-European study[J]. J Acquir Immune Defic Syndr, 2021,86(2):248-257.
[56] DE MONTE A, COURJON J, ANTY R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge[J]. J Clin Virol, 2016,78:27-30.
[57] LEE PK, KIEFFER TL, SILICIANO RF, et al. HIV-1 viral load blips are of limited clinical significance[J]. J Antimicrob Chemother, 2006,57(5):803-805.
[58] MITJà O, ALEMANY A, MARKS M, et al. Mpox in people with advanced HIV infection: a global case series[J]. Lancet, 2023, 401(10380):939-949.
[59] 中华医学会感染病学分会艾滋病丙型肝炎学组. 艾滋病免疫功能重建不全者临床诊疗专家共识(2023版)[J]. 中华传染病杂志,2024,42(1)：3-13.
[60] 中华医学会感染病学分会艾滋病学组, 中华医学会热带病和寄生虫学分会艾滋病学组. AIDS相关性淋巴瘤诊治专家共识[J].中国艾滋病性病, 2017, 23(8):678-682.
[61] YARCHOAN R, ULDRICK TS. HIV-associated cancers and related diseases[J]. N Engl J Med, 2018,378(11):1029-1041.
[62] PANEL ON TREATMENT OF HIV DURING PREGNANCY AND PREVENTION OF PERINATAL TRANSMISSION. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. [EB/OL].[2024-02-18].https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/guidelines-perinatal.pdf.
[63] 国家卫生健康委办公厅.预防艾滋病、梅毒和乙肝母婴垂直传播工作规范（2020年版）的通知[EB/OL]. (2020-11-12)[2024-02-21]. http://www.nhc.gov.cn/fys/s3581/202011/fc7b46b2b48b45a69bd390ae3a62d065.shtml.
[64] MYER L, PHILLIPS TK, MCINTYRE JA, et al. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa[J]. HIV Med, 2017,18(2):80-88.
[65] TOWNSEND CL, CORTINA-BORJA M, PECKHAM CS,et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006[J]. AIDS, 2008, 22(8):973-981.
[66] U.S. PUBLIC HEALTH SERVICE WORKING GROUP. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for post exposure prophylaxis[EB/OL]. [2024-03-09]. https://stacks.cdc.gov/view/cdc/20711.
[67] 中国疾病预防控制中心性病艾滋病预防控制中心.艾滋病病毒暴露后预防技术指南（试用）[EB/OL].[2024-03-09]. https://ncaids.chinacdc.cn/zxzx/zxzx/202011/W020201116802422550750.pdf.
[68] 张路坤 ,王辉. 中国HIV暴露前预防用药专家共识(2023版)[J].中国艾滋病性病, 2023, 29(9):954-961.
[69] NIE J, SUN F, HE X, et al. Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV post-exposure prophylaxis: a cohort study in China[J]. Infect Dis Ther, 2021, 10(4):2611-2623.
[70] SMITH CJ, RYOM L, WEBER R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration[J]. Lancet, 2014, 384(9939):241-248.
[71] WORLD HEALTH ORGANIZATION. Identifying common opportunistic infections among people with advanced HIV disease: policy brief[M/OL]. [2024-02-16]. https://iris.who.int/bitstream/handle/10665/375725/9789240084957-eng.pdf?sequence=1.
[72] 中华医学会热带病与寄生虫学分会艾滋病学组. 艾滋病合并侵袭性真菌病诊治专家共识[J]. 中华传染病杂志, 2019, 37(10)：581-593.
[73] CHEN S, HAN Y, SONG XJ, et al. Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-na?ve patients[J]. Infect Dis Poverty, 2020, 9(1):75.
[74] GUO F, CHENG X, HSIEH E, et al. Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study[J/OL] . HIV Med, [2024-03-28]. https://doi.org/10.1111/hiv.12607. [published online ahead of print].
[75] XU L, PENG W, SONG X, et al. Pharmacodynamics of efavirenz 400 mg in treatment-na?ve Chinese HIV-infected patients in a prospective cohort study[J]. BMC Infect Dis, 2021,21(1):112.
[76] DU X, PENG W, FU Q, et al. A review of clinical pharmacokinetic and pharmacodynamic profiles of select antiretrovirals: focus on differences among Chinese patients[J]. Pharmacotherapy, 2019,39(12):1179-1189.
[77] SHEN Y, LIU T, CHEN J, et al. Harnessing artificial intelligence to optimize long-term maintenance dosing for antiretroviral-naive adults with HIV-1 infection[J/OL]. Adv Therap, 2020, 3(4): 1900114. https://doi.org/10.1002/adtp.201900114.
[78] CHEN J, CHEN R, SHEN Y, et al. Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial[J]. Emerg Microbes Infect, 2020,9(1):843-850.
[79] 何小清,沈银忠,张仁芳,等. 未启动抗反转录病毒治疗的人类免疫缺陷病毒/艾滋病患者发生心血管疾病的风险评估[J]. 中华传染病杂志,2020,38(10)：640-645
[80] KANTERS S, RENAUD F, RANGARAJ A, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis[J]. EClinicalMedicine, 2022,48:101412.
[81] GUARALDI G, PALELLA FJ, JR. Clinical implications of aging with HIV infection: perspectives and the future medical care agenda[J]. AIDS, 2017,31 Suppl 2:S129-S135.
[82] WORLD HEALTH ORGANIZATION. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection[EB/OL].[2024-02-18]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1.
[83] 中华医学会感染病学分会艾滋病丙型肝炎学组. 成人人类免疫缺陷病毒感染者新型冠状病毒疫苗接种专家建议[J]. 中华内科杂志,2021,60(7)：615-618.